EPx4 Raises Odds of Renal, Nerve, Hearing Harms - Takeaways - MDSpire

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • By

  • Kerri Miller

  • February 25, 2026

  • 5 min

Share

  • 1

    Long-term survivors of testicular cancer treated with EPx4 face higher odds of renal impairment, ototoxicity, and peripheral neuropathy compared to BEPx3.

  • 2

    The study analyzed 798 patients who completed cisplatin-based chemotherapy, with a median follow-up age of 45 years and median time since treatment of 11 years.

  • 3

    Patients receiving EPx4 had 1.55 times the odds of renal impairment and 1.48 times the odds of hearing loss compared to those treated with BEPx3.

  • 4

    41% of patients exhibited reduced eGFR below 90 mL/min/1.73 m², exceeding US population norms, with significant associations to hypertension and cardiovascular disease.

  • 5

    Chemotherapy regimen significantly impacted self-reported global physical health, with BEPx4 and VIPx4 showing the most pronounced reductions in health scores.

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

  • by Kerri Miller

  • February 25, 2026

Related Content

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

Does Structured Reporting Improve Lung Cancer Reports?

A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.